Prognose

Kaufen	1
Halten	1
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal
PALO ALTO, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced a publication on GLOPERBA® dosing adjustments in peer-review journal.» Mehr auf globenewswire.com
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL
PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today presented the presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.» Mehr auf globenewswire.com
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.
PALO ALTO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced an upcoming presentation of post-hoc analysis of the C.L.E.A.R.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Scilex Holding Co einen Umsatz von 4,63 Mio€ und ein Nettoeinkommen von −24,11 Mio€

(EUR)	März 2025	YOY
Umsatz	+4,63 Mio	54,13%
Bruttoeinkommen	+3,35 Mio	39,94%
Nettoeinkommen	−24,11 Mio	6,73%
EBITDA	−25,79 Mio	21,99%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+37,61 Mio€
Anzahl Aktien	6,95 Mio
52 Wochen-Hoch/Tief	+70,47€ - +3,15€
Dividenden	Nein
Beta	1,14
KGV (PE Ratio)	−0,96
KGWV (PEG Ratio)	0,00
KBV (PB Ratio)	−0,34
KUV (PS Ratio)	+0,85